Relatlimab and nivolumab in the treatment of melanoma


Combined LAG-3 and PD-1 blockade is an emerging strategy for the treatment of melanoma. Tawbi et al. and Amaria et al. report in The New England Journal of Medicine and Nature respectively on two clinical trials evaluating relatlimab and nivolumab as front-line treatment for metastatic, and resectable, high-risk, node-positive melanoma.

Journal details

Journal Cell
Volume 185
Issue number 26
Pages 4866-4869
Available online
Publication date

Crick authors

Crick First author
Crick Corresponding author